Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Feb 19:2024.02.15.580166.
doi: 10.1101/2024.02.15.580166.

Metformin Enhances Antibody-Mediated Recognition of HIV-Infected CD4+ T-Cells by Decreasing Viral Release

Affiliations

Metformin Enhances Antibody-Mediated Recognition of HIV-Infected CD4+ T-Cells by Decreasing Viral Release

Augustine Fert et al. bioRxiv. .

Abstract

The mechanistic target of rapamycin (mTOR) positively regulates multiple steps of the HIV-1 replication cycle. We previously reported that a 12-weeks supplementation of antiretroviral therapy (ART) with metformin, an indirect mTOR inhibitor used in type-2 diabetes treatment, reduced mTOR activation and HIV transcription in colon-infiltrating CD4+ T-cells, together with systemic inflammation in nondiabetic people with HIV-1 (PWH). Herein, we investigated the antiviral mechanisms of metformin. In a viral outgrowth assay performed with CD4+ T-cells from ART-treated PWH, and upon infection in vitro with replication-competent and VSV-G-pseudotyped HIV-1, metformin decreased virion release, but increased the frequency of productively infected CD4lowHIV-p24+ T-cells. These observations coincided with increased BST2/Tetherin (HIV release inhibitor) and Bcl-2 (pro-survival factor) expression, and improved recognition of productively infected T-cells by HIV-1 Envelope antibodies. Thus, metformin exerts pleiotropic effects on post-transcription/translation steps of the HIV-1 replication cycle and may be used to accelerate viral reservoir decay in ART-treated PWH.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST The authors declare no competing interests.

Figures

Figure 1:
Figure 1:. Effects of metformin on viral outgrowth in memory CD4+ T-cells from ART-treated PWH.
(A) Shown is the flow chart for the viral outgrowth assay (VOA). Briefly, memory CD4+ T-cells from ART-treated PWH were stimulated with CD3/CD28 Abs, in the presence (n=11) or the absence (n=6) of ARVs and in the presence/absence of metformin (1 mM) or INK128 (50 nM) for 3 days. Supernatants were collected, cells were split in two news wells, and media containing IL-2 and metformin or INK128 was refreshed every 3 days. Experiments were performed in 4–8 original replicates per condition. One original replicate at day 0 generated 8 final replicates at day 12. At the end of the experiment, T-cells derived from the same original replicate were merged for PCR and flow cytometry analysis. Shown are (B) integrated HIV-DNA levels quantified by real-time nested PCR and (C) levels of HIV-p24 in cell-culture supernatants quantified by ELISA. Shown are (D) representative flow cytometry dot plot of intracellular HIV-p24 and surface CD4 expression; (E) statistical analysis of the frequency of CD4lowHIV-p24+, (F) the frequency of CD4highHIV-p24+ cells; and (G) the geometric MFI (GeoMFI) of HIV-p24 expression in CD4low HIV-p24+ and CD4high HIV-p24+ T-cell subsets. Each symbol represents one donor; bars indicate the median ± interquartile range. Kruskal-Wallis test and uncorrected Dunn’s multiple comparison p-values are indicated on the graphs.
Figure 2:
Figure 2:. Effects of metformin on HIV-1 transcription in memory CD4+ T-cells of ART-treated PWH.
(A) Shown is the experimental flow chart. Briefly, memory CD4+ T-cells from ART-treated PWH were stimulated by CD3/CD28 Abs in presence of ARVs (Saquinavir 5 μM, Raltegravir 200 nM) and in the presence or the absence of metformin (1 mM) or INK128 (50 nM) for 3 days. Cells were collected for dual extraction of cell-associated (CA) RNA and DNA. (B) Levels of integrated HIV-DNA Alu/LTR primers were quantified by nested real-time PCR and normalized per number of CD3 copies. (C) Levels of CA unspliced (US) HIV-RNA (Gag primers) were quantified by nested real-time RT-PCR and normalized to the number of HIV-DNA copies per 106 cells. (D) The HIV RNA/DNA ratio was used as a surrogate marker of HIV-1 transcription. Each symbol represents one donor (n=7; median ± interquartile range). Friedman p-values are indicated on the graphs. Uncorrected Dunn’s multiple comparison p-values did not reach statistical significance and are not shown.
Figure 3:
Figure 3:. Effects of metformin on HIV-1 replication in vitro in memory CD4+ T-cells.
(A) Shown is the flow chart for the HIV-1 infection in vitro. Briefly, memory CD4+ T-cells from HIV-uninfected donors were stimulated with anti-CD3/CD28 Abs in the absence/presence of metformin (1 mM) or INK128 (50 nM) for 3 days. Then, cells were exposed to the replication-competent NL4.3BaL HIV strain (50 ng HIV-p24/106 cells). Cell-culture supernatants were collected and media containing IL-2 and/or metformin or INK128 was refreshed every 3 days until day 12 post-infection. (B) Integrated HIV-DNA levels were quantified by real-time nested PCR at day 3 post infection. Shown are (C) levels of HIV-p24 in cell-culture supernatants quantified by ELISA in one representative donor, and (D) statistical analysis of HIV-1 replication at day 9 post-infection in cells from n=8 different donors. Shown is (E) the dot plot analysis of the intracellular HIV-p24 and surface CD4 expression allowing the identification of CD4lowHIV-p24+ cells (productively infected) and CD4highHIV-p24+ cells (recently infected); as well as (F) the statistical analysis of CD4lowHIV-p24+ T-cells frequency and (G) the geometric MFI of HIV-p24 expression. Shown are the statistical analysis (H) of CD4highHIV-p24+ T-cells frequency and (I) the geometric MFI of HIV-p24 expression. Each symbol represents 1 donor (n=8; median ± interquartile range). Friedman and uncorrected Dunn’s multiple comparison p-values are indicated on the graphs
Figure 4:
Figure 4:. Effects on metformin on single-round HIV-1 infection in vitro.
(A) Shown is the flow chart for the single-round HIV-1 infection in vitro. Briefly, memory CD4+ T-cells from HIV-uninfected donors were stimulated by anti-CD3/CD28 Abs in the absence/presence of metformin (1 mM) or INK128 (50 nM) for 3 days. Then, cells were exposed to a replication-incompetent single-round VSV-G-pseudotyped HIV-1 construct (100 ng HIV-p24/106 cells). Cell-culture supernatants and cells were collected at day 3 post-infection. Shown are levels of early (RU5) (B) and late HIV reverse transcripts (Gag) (C), as well as integrated HIV-DNA (D) quantified by real-time nested PCR. Shown are representative flow cytometry dot plots of intracellular HIV-p24 and surface CD4 expression from one donor (E) and statistical analysis of the productively infected CD4lowHIV-p24+ T-cells in terms of frequencies (F) and the geometric MFI of HIV-p24 expression (G). Shown are absolute HIV-p24 levels in cell culture supernatants quantified by ELISA (H). Each symbol represents one donor (n=7; median ± interquartile range). Friedman and uncorrected Dunn’s multiple comparison p-values are indicated on the graphs
Figure 5:
Figure 5:. Metformin and INK128 increases BST2 expression on productively infected CD4lowHIV-p24+ T-cells.
(A) Shown are representative flow cytometry dot plots of BST2 and HIV-p24 co-expression on T-cells at day12 post-infection with HIV-1NL4.3 Bal in vitro (upper panel) and at day 12 post TCR-mediated viral reservoir reactivation in VOA (bottom panel). (B-C) The HIV-1NL4.3Bal infection in vitro was performed as described in Figure 3 on cells from n=8 HIV-uninfected participants. Cells collected at day 12 post-infection were stained on the surface with CD4 and BST2 antibodies and intracellularly with HIV-p24 antibodies and analyzed by flow cytometry for n=8. Shown are (B) levels of BST2 expression on uninfected (CD4highHIV-p24) and productively infected (CD4lowHIV-p24+) T-cells in one representative donor and (C) statistical analysis of BST2 expression (GeoMFI) relative to the medium condition (considered 1). (D-E) The VOA was performed as described in Figure 1 with cells from n=6 ART-treated PWH. Cells collected at day 12 post-stimulation were stained on the surface with CD4 and BST2 Abs and intracellularly with HIV-p24 Abs and analyzed by flow cytometry. (D-E) Shown are levels of BST2 expression on CD4highHIV-p24 and CD4lowHIV-p24+ T-cells in (D) one representative donor and (E) statistical analysis of BST2 expression (absolute GeoMFI). (F) Shown is the BST2 expression relative to the medium condition of HIV-uninfected memory CD4+ T-cells at day 3 post-TCR stimulation. Each symbol represents one donor (median ± interquartile range). Friedman (C and F), Kuskal-Wallis (E) and uncorrected Dunn’s multiple comparison p-values are indicated on the graphs
Figure 6:
Figure 6:. Metformin increases Bcl-2 expression on HIV-infected and uninfected T-cells.
The HIV-1NL4.3Bal infection in vitro was performed as described in Figure 3 on cells from HIV-uninfected participants. Cells collected at day 12 post-infection were stained on the surface with CD4 antibodies and intracellularly with HIV-p24 and Bcl-2 antibodies and analyzed by flow cytometry. Shown are (A) levels of Bcl-2 expression on uninfected (CD4highHIV-p24) and productively infected (CD4lowHIV-p24+) T-cells in one representative donor and (B) statistical analysis of Bcl-2 expression (GeoMFI) relative to the medium condition (considered 1). Each symbol represents one donor (n=4; median ± interquartile range). Friedman and uncorrected Dunn’s multiple comparison p-values are indicated on the graphs.
Figure 7:
Figure 7:. Metformin facilitates the recognition of reactivated HIV reservoirs by anti-HIV Env antibodies.
The VOA was performed on memory CD4+ T-cells from ART-treated PWH, as described in Figure 1A. Cells harvested at day 12 post-TCR triggering and cultured in the presence/absence of metformin were stained on the surface with a set of unconjugated human anti-HIV-1 Env bNAbs (2G12, PGT121, PGT126, PGT151, 3BNC117, 101074, VRC03) and nnAbs (F240, 17b, A32), followed by incubation with anti-human Alexa Fluor 647-conjugated secondary Abs. Further, cells were stained on the surface with CD4 Abs, as well as intracellularly with HIV-p24 Abs. (A) Show are dot plot representations of HIV-p24 and HIV-Env co-expression in one representative donor. (B-C) Shown are statistical analysis of the frequency of anti-HIV-Env Abs binding on CD4lowHIV-p24+ T-cells (B), as well as the geometric MFI of anti-HIV-Env Abs binding on CD4lowHIV-p24+ T-cells (C). Wilcoxon test p-values are indicated on the graphs. Each symbol represents one donor (n=8; median ± interquartile range).

Similar articles

References

    1. Bai R.J., Dai L.L., and Wu H. (2020). Advances and challenges in antiretroviral therapy for acquired immunodeficiency syndrome. Chin Med J (Engl) 133, 2775–2777. 10.1097/CM9.0000000000001226. - DOI - PMC - PubMed
    1. Hsue P.Y., and Waters D.D. (2018). Time to Recognize HIV Infection as a Major Cardiovascular Risk Factor. Circulation 138, 1113–1115. 10.1161/CIRCULATIONAHA.118.036211. - DOI - PMC - PubMed
    1. So-Armah K., Benjamin L.A., Bloomfield G.S., Feinstein M.J., Hsue P., Njuguna B., and Freiberg M.S. (2020). HIV and cardiovascular disease. Lancet HIV 7, e279–e293. 10.1016/S2352-3018(20)30036-9. - DOI - PMC - PubMed
    1. Wang C.C., Silverberg M.J., and Abrams D.I. (2014). Non-AIDS-Defining Malignancies in the HIV-Infected Population. Curr Infect Dis Rep 16, 406. 10.1007/s11908-014-0406-0. - DOI - PMC - PubMed
    1. Samaras K., Wand H., Law M., Emery S., Cooper D., and Carr A. (2007). Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 30, 113–119. 10.2337/dc06-1075. - DOI - PubMed

Publication types